Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001846444-25-000017
Filing Date
2025-08-13
Accepted
2025-08-13 11:27:31
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 13650
  Complete submission text file 0001846444-25-000017.txt   15471
Mailing Address 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465
Business Address 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465 617-344-4190
Acumen Pharmaceuticals, Inc. (Subject) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92677 | Film No.: 251209714
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209
Business Address 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209 703-562-4000
Sands Capital Alternatives, LLC (Filed by) CIK: 0001846444 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: SCHEDULE 13G/A